• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Congratulation Roger and Ken!

Quote
That's what Merck is now. A real estate and law firm. Buy a firm that bought a firm that had some good products. Rush it to market, and then spend the next 10 years of profits lawyering against the patent infringement lawsuits and wrongful death lawsuits. The Vioxx kid will be very busy.
 




Thats the beauty of cancer drugs - patient is already VERY sick - very unpredictable if the drug will work or not, patients are more than willing to take the risk - very doubtful any lawsuits will come if things don't work out.
 








Anonymous said:
Pat Roger and Ken on the back all you want for finally getting a drug approved. However, do not count you chickens before they have hatched. Revenues in proportion to the needs of the company is what matters and that success should not be considered a forgone conclusion at this point.
Click to expand...

Kinda like Obama taking credit for ending the war in Iraq. Oh...wait.
 




Anonymous said:
What and amazing display of competence, focus, and resolve...."Keytruda embodies Merck's unwavering commitment to pursue breakthrough science to help people who are facing the most challenging diseases," CEO Kenneth Frazier said in a statement.
Click to expand...

Ask yourself if any of the scientists (legacy Organon/SP or Merck) who invented PD-1 are still at Merck. It's easy to check.

The unwavering commitment is to reduce headcount.
 




Anonymous said:
I see Merck had to but SP to get this drug. Time will tell if Merck ever recoups their investment.
Click to expand...

If only. The PD-1 program at legacy SP was below the cut line, not on the radar at all. (It was killed and brought back multiple times.) Fortunately, the SP folks had managed to bank a lot of PD-1 mAb in the freezer before it was killed again, so we were able to restart relatively quickly.
 




Anonymous said:
If only. The PD-1 program at legacy SP was below the cut line, not on the radar at all. (It was killed and brought back multiple times.) Fortunately, the SP folks had managed to bank a lot of PD-1 mAb in the freezer before it was killed again, so we were able to restart relatively quickly.
Click to expand...

But not before BMS got the patent on it. Merck lost the EU patent fight on it and Friday BMS filed suit in the U.S. BMS noted in their filing that Merck knew they did not have the patent rights because they had lost in the EU on the exact same issue. BMS will seek to block Merck from manufacturing the drug and, if the lawsuit goes forward (i.e. no settlement) BMS will use the fact that Merck forged ahead after losing the EU case to demonstrate 'willfullness'. Why does that matter? Oh, because if they can prove it (looks like an easy task) the damages amount TRIPLES under law from any jury award.

This has 'reverse merger' written all over it. Remember that? When the legal eagles of Merck thought they had come up with a way to buy Schering and screw J&J out of Remicaide? Instead Merck paid a premium for Schering and then had to BUY the rights from J&J. The best lawyers money can buy!
 




Anonymous said:
But not before BMS got the patent on it. Merck lost the EU patent fight on it and Friday BMS filed suit in the U.S. BMS noted in their filing that Merck knew they did not have the patent rights because they had lost in the EU on the exact same issue. BMS will seek to block Merck from manufacturing the drug and, if the lawsuit goes forward (i.e. no settlement) BMS will use the fact that Merck forged ahead after losing the EU case to demonstrate 'willfullness'. Why does that matter? Oh, because if they can prove it (looks like an easy task) the damages amount TRIPLES under law from any jury award.

This has 'reverse merger' written all over it. Remember that? When the legal eagles of Merck thought they had come up with a way to buy Schering and screw J&J out of Remicaide? Instead Merck paid a premium for Schering and then had to BUY the rights from J&J. The best lawyers money can buy!
Click to expand...


Hey Kenny.....payback's a bitch, ain't it?
 












Anonymous said:
What and amazing display of competence, focus, and resolve...."Keytruda embodies Merck's unwavering commitment to pursue breakthrough science to help people who are facing the most challenging diseases," CEO Kenneth Frazier said in a statement.
Click to expand...

Not sure commercial side is up to task of making this happen.
 




Re: Congratulation Roger and Ken!?

Anonymous said:
What and amazing display of competence, focus, and resolve...."Keytruda embodies Merck's unwavering commitment to pursue breakthrough science to help people who are facing the most challenging diseases," CEO Kenneth Frazier said in a statement.
Click to expand...

Mr. Subliminal here-
"Keytruda embodies <management's> un<abashed> commitment to pursue <breakneck speed and profit margins at everyone else's expense> to help <us> who are <nosing up> the <ass of Wall Street>.
 




Anonymous said:
Cramer should be concerned...While Rodger and Ken can pat themselves for the speed with which this breakthrough was approved, the fact of the matter is the know- it- all MRL leadership sat on this compound- which BTW was developed by Organon---- for nearly three years while they build power point slides and committees to review the power point slides. They gutted almost every program, in both Oncology and PC to fund this catch up. Brilliant.
Click to expand...

One distinction:
Roger knows how to develop drugs and is making changes.
Ken is making changes but does not know how to develop a company.

I wonder what the random initiative generator will spit out and the flavor of the year for 2015.
 








Top Bottom
Back
Quote